pyrotinib combined with capecitabine

DRUG3 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., Fudan University, Peking Union Medical College Hospital

Conditions

Early-stage Breast CancerHER2-positive Breast CancerMetastatic Breast Cancer

Phase 1

Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer

CompletedNCT02361112

Jiangsu HengRui Medicine Co., Ltd.Metastatic Breast Cancer

Start: 2014-08-31End: 2016-12-31Target: 38Updated: 2018-07-09

Phase 2

Pyrotinib in Combination With Capecitabine in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer

Fudan UniversityMetastatic Breast Cancer

Start: 2019-06-26End: 2023-12-31Target: 100Updated: 2022-12-08

Unknown Phase

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

RecruitingNCT06035016

Peking Union Medical College HospitalEarly-stage Breast Cancer, HER2-positive Breast Cancer

Start: 2023-06-01End: 2027-06-01Target: 300Updated: 2023-09-13

Related Papers

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

BMC Medicine2023-08-0917 citations

Abstract P4-01-43: PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

Cancer Research2023-03-01

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies.

2023-02-207 citations

Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer.

Journal of Clinical Oncology2022-06-012 citations

Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial.

Journal of Clinical Oncology2019-05-203 citations